MANH Form 4 — Richards Bruce Receives 974 RSUs; Ownership 25,602
Rhea-AI Filing Summary
Form 4 summary — Manhattan Associates, Inc. (MANH)
On 07/30/2025 Richards Bruce, reported as SVP, CLO & Secretary, was granted 974 restricted stock units (RSUs) under the issuer's stock incentive plan. The transaction is reported as an acquisition at a recorded price of $0.0000. Following the grant, the filing shows Bruce beneficially owns 25,602 shares of common stock. The RSUs vest 25% on January 31 of each year following the grant date until fully vested, per the explanation in the filing. The Form 4 was signed by attorney-in-fact David M. Eaton on 08/04/2025. Table II reports no derivative securities.
Positive
- Grant recorded: 974 restricted stock units granted on 07/30/2025
- Vesting schedule disclosed: 25% vesting on January 31 each year until fully vested
- Post-transaction ownership: Reporting person beneficially owns 25,602 shares following the grant
- Timely execution: Form signed by attorney-in-fact David M. Eaton on 08/04/2025
Negative
- None.
Insights
TL;DR: Senior officer received 974 RSUs on 07/30/2025; routine compensation disclosure with no derivatives reported.
The filing documents an equity grant to Richards Bruce, identified as SVP, CLO & Secretary, consisting of 974 restricted stock units recorded as an acquisition on 07/30/2025. The grant is described as subject to a standard multi-year vesting schedule of 25% on January 31 each year until fully vested. Following the grant Bruce's reported beneficial ownership is 25,602 shares. The Form 4 was executed by an attorney-in-fact on 08/04/2025. Based solely on the filing, this appears to be a routine equity compensation disclosure without reported derivative transactions.
TL;DR: Form 4 discloses an RSU grant to an officer with explicit vesting terms; disclosure appears compliant and procedural.
The document is a Section 16 Form 4 reporting an acquisition of 974 RSUs by Richards Bruce under the company stock incentive plan. The filing specifies a vesting cadence of 25% on January 31 of each year post-grant until full vesting and reports total beneficial ownership of 25,602 shares after the transaction. No derivative securities are listed in Table II. The Form bears a signature date of 08/04/2025 by an attorney-in-fact, consistent with required procedural disclosure for insider awards.